Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

被引:176
作者
Kamali, F [1 ]
Khan, TI [1 ]
King, BP [1 ]
Frearson, R [1 ]
Kesteven, P [1 ]
Wood, P [1 ]
Daly, AK [1 ]
Wynne, H [1 ]
机构
[1] Newcastle Univ, Sch Clin & Lab Sci, Royal Victoria Hosp, Dept Care Elderly, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
D O I
10.1016/j.clpt.2003.10.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Our objective was to assess the contribution of CYP2C9 genotype, age, body size, and vitamin K and lipid status to warfarin dose requirements. Methods: Patients with stable warfarin dose requirements and an international normalized ratio (INR) of the prothrombin time within the target range of 2.0 to 3.0 were recruited to the study. On arrival at the clinic in the morning, after an overnight fast, a blood sample was taken from each patient for CYP2C9 genotyping and for determination of venous INR and plasma vitamin K R- and S-warfarin, and triglyceride concentrations. Results. A total of 121 patients were recruited to the study. CYP2C9 genotyping showed that 74 patients were homozygous wild-type (*1/*1), 30 were heterozygous *1/*2, and 15 were heterozygous *1/*3 genotype. One patient was found to have the genotype *2/*3, and another was found to have the genotype *3/*3. The mean warfarin daily dose requirement in milligrams fell from 4.06 +/- 1.72 mg in homozygous wild-type patients to 3.63 +/- 1.78 mg for *1/*2-positive patients and 2.70 +/- 1.36 mg for *1/*3-positive patients. The multiple linear regression model for warfarin dose indicated significant contributions from age (r = 0.41, P < .001), genotype (r = 0.24, P < .005), and age and genotype together (r = 0.45, P < .005). Although there were significant linear correlations between warfarin dose and body surface area (r = 0.21, P =.02), body weight (r = 0.25, P = .005), and plasma vitamin K concentration (r = 0.18, P < .05), none of these variables made a significant contribution to the regression model for warfarin dose. CYP2C9 genotype had a significant effect on S-warfarin clearance (r = 0.34, P < .0001) but none on R-warfarin clearance. Conclusion: This study showed that age and CYP2C9 polymorphism affect warfarin dose requirements in patients receiving long-term therapy and having stable control of anticoagulation. It is anticipated that using dosing regimens modified to take into account the contribution of age and CYP2C9 genotype has the potential to improve the safety of warfarin therapy.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 24 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] BUCOLO G, 1973, CLIN CHEM, V19, P476
  • [3] CYP2D6 multiallelism
    Daly, AK
    Steen, VM
    Fairbrother, KS
    Idle, JR
    [J]. CYTOCHROME P450, PT B, 1996, 272 : 199 - 210
  • [4] Davidson KW, 1997, METHOD ENZYMOL, V282, P408
  • [5] A formula to estimate the approximate surface area if height and weight be known
    Du Bois, D
    Du Bois, EF
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1916, 17 (06) : 863 - 871
  • [6] EFFECT OF AGE UPON THE INDUCTION AND MAINTENANCE OF ANTICOAGULATION WITH WARFARIN
    GLADMAN, JRF
    DOLAN, G
    [J]. POSTGRADUATE MEDICAL JOURNAL, 1995, 71 (833) : 153 - 155
  • [7] Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
    Haining, RL
    Hunter, AP
    Veronese, ME
    Trager, WF
    Rettie, AE
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) : 447 - 458
  • [8] Temporal variations in plasma vitamin K and lipid concentrations and clotting factor activity in humans
    Kamali, F
    Edwards, C
    Wood, P
    Wynne, HA
    Kesteven, P
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2001, 68 (03) : 159 - 163
  • [9] LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449
  • [10] Interindividual variability in sensitivity to warfarin - Nature or nurture?
    Loebstein, R
    Yonath, H
    Peleg, D
    Almog, S
    Rotenberg, M
    Lubetsky, A
    Roitelman, J
    Harats, D
    Halkin, H
    Ezra, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) : 159 - 164